Huaier aqueous extract suppresses human breast cancer cell proliferation through inhibition of estrogen receptor α signaling

Wang,Xiaolong; Zhang,Ning; Huo,Qiang; Sun,Mingjuan; Lv,Shangge; Yang,Qifeng

doi:10.3892/ijo.2013.1947

Huaier aqueous extract suppresses human breast cancer cell proliferation through inhibition of estrogen receptor α signaling

Authors:
- Xiaolong Wang
- Ning Zhang
- Qiang Huo
- Mingjuan Sun
- Shangge Lv
- Qifeng Yang
View Affiliations

Affiliations: Department of Breast Surgery, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China
Published online on: May 20, 2013 https://doi.org/10.3892/ijo.2013.1947
Pages: 321-328

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Estrogen receptor α (ERα) has been reported to play a critical role in promoting the growth of breast tumor cells. In the present study, we explored the effect of Huaier extract on estrogen receptor α signaling in breast cancer cell lines. Our data demonstrated that Huaier extract effectively inhibited the proliferation of the MCF-7, T47D and ZR-75-1 human breast cancer cell lines. For the mechanism analysis, we demonstrated that Huaier extract significantly reduced the mRNA and protein levels of ERα in all three ERα-positive cell lines. The downregulation of ERα protein levels was correlated with activation of the proteasomes. We demonstrated that Huaier extract markedly decreased the expression of both ERα and its downstream genes, inhibited the estrogen-stimulated proliferation and reversed the estrogen-induced activation of the nuclear factor κB (NFκB) pathway. Our study provides evidence that Huaier extract is a novel estrogen receptor modulator and is a promising drug for the prevention and treatment of ERα-positive human breast cancers.

View Figures

View References

1.	Hedden A, Müller V and Jensen EV: A new interpretation of antiestrogen action. Ann NY Acad Sci. 761:109–120. 1995. View Article : Google Scholar : PubMed/NCBI
2.	Klinge CM: Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29:2905–2919. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Kushner PJ, Agard DA, Greene GL, et al: Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol. 74:311–317. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Safe S: Transcriptional activation of genes by 17β-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm. 62:231–252. 2001.
5.	Dotzlaq H, Leygue E, Watson PH and Murphy LC: Expression of estrogen receptor-β in human breast tumors. J Clin Endocrinol Metab. 82:2371–2374. 1997.
6.	Ali S and Coombes RC: Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia. 5:271–281. 2000. View Article : Google Scholar : PubMed/NCBI
7.	Korach KS, Couse JF, Curtis SW, et al: Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. Recent Progr Horm Res. 51:1591996.PubMed/NCBI
8.	Bocchinfuso WP and Korach KS: Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia. 2:323–334. 1997. View Article : Google Scholar : PubMed/NCBI
9.	Shaaban AM, O’Neill PA, Davies MPA, et al: Declining estrogen receptor-[beta] expression defines malignant progression of human breast neoplasia. American J Surg Pathol. 27:1502–1512. 2003.
10.	Gralow JR: Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 89:9–15. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Shang Y and Brown M: Molecular determinants for the tissue specificity of SERMs. Science. 295:2465–2468. 2002. View Article : Google Scholar : PubMed/NCBI
12.	Osborne CK, Zhao HH and Fuqua SAW: Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 18:3172–3186. 2000.PubMed/NCBI
13.	McCarthy TL, Clough ME, Gundberg CM and Centrella M: Expression of an estrogen receptor agonist in differentiating osteoblast cultures. Proc Natl Acad Sci USA. 105:7022–7027. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Cassady JM, Baird WM and Chang CJ: Natural products as a source of potential cancer chemotherapeutic and chemopreventive agents. J Nat Prod. 53:23–41. 1990.PubMed/NCBI
15.	Zhang N, Kong X, Yan S, Yuan C and Yang Q: Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci. 101:2375–2383. 2010. View Article : Google Scholar : PubMed/NCBI
16.	Wang X, Zhang N, Huo Q and Yang Q: Anti-angiogenic and antitumor activities of Huaier aqueous extract. Oncol Rep. 28:1167–1175. 2012.PubMed/NCBI
17.	Ren J, Zheng C, Feng G, et al: Inhibitory effect of extract of fungi of Huaier on hepatocellular carcinoma cells. J Huazhong Univ Sci Technolog Med Sci. 29:198–201. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Xu X, Wei Q, Wang K, et al: Anticancer effects of Huaier are associated with down-regulation of P53. Asian Pac J Cancer Prev. 12:2251–2254. 2011.PubMed/NCBI
19.	Sun Y, Sun T, Wang F, et al: A polysaccharide from the fungi of Huaier exhibits anti-tumor potential and immunomodulatory effects. Carbohydr Polym. 92:577–582. 2013. View Article : Google Scholar : PubMed/NCBI
20.	Lippman M, Bolan G and Huff K: The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36:4595–4601. 1976.PubMed/NCBI
21.	Dupont J, Karas M and LeRoith D: The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem. 275:35893–35901. 2000. View Article : Google Scholar : PubMed/NCBI
22.	Zhu J, Li X, Kong X, et al: Testin is a tumor suppressor and prognostic marker in breast cancer. Cancer Sci. 103:2092–2101. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Altucci L, Addeo R, Cicatiello L, et al: 17beta-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G (1)-arrested human breast cancer cells. Oncogene. 12:23151996.
24.	Kodama F, Greene GL and Salmon SE: Relation of estrogen receptor expression to clonal growth and antiestrogen effects on human breast cancer cells. Cancer Res. 45:2720–2724. 1985.PubMed/NCBI
25.	Lu J, Pierron A and Ravid K: An adenosine analogue, IB-MECA, down-regulates estrogen receptor α and suppresses human breast cancer cell proliferation. Cancer Res. 63:6413–6423. 2003.PubMed/NCBI
26.	Wormke M, Stoner M, Saville B, et al: The aryl hydrocarbon receptor mediates degradation of estrogen receptor α through activation of proteasomes. Mol Cell Biol. 23:1843–1855. 2003.
27.	Wijayaratne AL and McDonnell DP: The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem. 276:35684–35692. 2001.
28.	Horwitz KB, Koseki Y and McGuire WL: Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinology. 103:1742–1751. 1978. View Article : Google Scholar : PubMed/NCBI
29.	Dauvois S, White R and Parker MG: The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 106:1377–1388. 1993.PubMed/NCBI
30.	Baker P, Wilton J, Jones C, Stenzel D, Watson N and Smith G: Bile acids influence the growth, oestrogen receptor and oestrogen-regulated proteins of MCF-7 human breast cancer cells. Br J Cancer. 65:5661992. View Article : Google Scholar : PubMed/NCBI
31.	Horwitz KB, Mockus MB and Lessey BA: Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell. 28:633–642. 1982. View Article : Google Scholar
32.	Rubio M, Werbajh S, Cafferata E, et al: TNF-alpha enhances estrogen-induced cell proliferation of estrogen-dependent breast tumor cells through a complex containing nuclear factor-kappa B. Oncogene. 25:1367–1377. 2005. View Article : Google Scholar
33.	Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1371–1388. 1998. View Article : Google Scholar : PubMed/NCBI
34.	Ali S and Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2:101–112. 2002. View Article : Google Scholar : PubMed/NCBI
35.	Yao K and Jordan VC: Questions about tamoxifen and the future use of antiestrogens. Oncologist. 3:104–110. 1998.PubMed/NCBI
36.	Cortesi L, De Matteis E, Rashid I, et al: Distribution of second primary malignancies suggests a bidirectional effect between breast and endometrial cancer: a population-based study. Int J Gynecol Cancer. 19:13582009. View Article : Google Scholar
37.	Gutierrez MC, Detre S, Johnston S, et al: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 23:2469–2476. 2005. View Article : Google Scholar
38.	Levin ER: Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 17:309–317. 2003. View Article : Google Scholar : PubMed/NCBI
39.	Osborne C, Wakeling A and Nicholson R: Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 90:S2–S6. 2004. View Article : Google Scholar : PubMed/NCBI
40.	Buijs C, de Vries EG, Mourits MJ and Willemse PH: The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat Rev. 34:640–655. 2008. View Article : Google Scholar : PubMed/NCBI
41.	Klinge CM: Estrogen receptor interaction with co-activators and co-repressors. Steroids. 65:227–251. 2000. View Article : Google Scholar : PubMed/NCBI
42.	Hsu SM, Chen YC and Jiang MC: 17β-estradiol inhibits tumor necrosis factor-α-induced nuclear factor-κB activation by increasing nuclear factor-κB p105 level in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 279:47–52. 2000.